COVID-19 Vaccination Response in Participants Across Clinical Trials Investigating Efgartigimod PH20 SC (P9-11.029)
To investigate the effect of treatment with efgartigimod [administered intraveniously (IV) or subcutaneously (SC, coformulated with recombinant human hyaluronidase PH20)], a human immunoglobulin G1 (IgG1) antibody Fc-fragment that reduces total and pathogenic IgG levels through neonatal Fc receptor blockade, on humoral immune responses to COVID-19 vaccination in participants with various antibody-mediated autoimmune diseases, including generalized myasthenia gravis (gMG).
Authors
- Kevin L. Winthrop (ORCID: https://orcid.org/0000-0002-3892-6947)
- Tuan Vu (ORCID: https://orcid.org/0000-0003-0724-0210)
- Francesco Saccà (ORCID: https://orcid.org/0000-0002-1323-6317)
- Renato Mantegazza (ORCID: https://orcid.org/0000-0002-9810-5737)
- James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
- John W. Sleasman (ORCID: https://orcid.org/0000-0003-0078-5867)
- P. Duncombe
- Sophie Steeland
- Antoine Azar (ORCID: https://orcid.org/0000-0003-0782-9084)
- Benjamin Van Hoorick
- Jan De Bleecker (ORCID: https://orcid.org/0000-0002-1328-1812)
- Ali A. Habib (ORCID: https://orcid.org/0000-0003-3432-9747)
- Fien Gistelinck
Institutions
- Johns Hopkins University (US)
- Oregon Health & Science University (US)
- Duke University (US)
- University of South Florida (US)
- Johns Hopkins Medicine (US)
- Ghent University Hospital (BE)
- University of California System (US)
- Federico II University Hospital (IT)
- Argenx (Belgium) (BE)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210685
- Primary Topic
- Transgenic Plants and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00